Cell and Gene Therapy Biomanufacturing Market Research Report Information By Product Type (Consumables, Equipment and Software Solutions), By Usage (Commercial Stage Manufacturing and Research Stage Manufacturing), By Application (Upstream Processing, Harvesting and Downstream Processing), By End User (Life Science Companies, Contract Research Organizations, Contract Manufacturing Organizations and Cell Banks) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Industry Forecast Till 2032
The market size for cell and gene therapy biomanufacturing was estimated at USD 12.6 billion in 2022. The market for cell and gene therapy biomanufacturing is expected to expand at a compound annual growth rate (CAGR) of 10.60% between 2024 and 2032, from an estimated USD 13.9 billion in 2023 to USD 31.2 billion by 2032. The main factors propelling the market expansion are rising investments in gene and cell therapy research.
The market for cell and gene therapy is expanding quickly, which is driving the market for cell and gene therapy biomanufacturing by increasing demand for manufacturing solutions. As innovative cell and gene therapies get approval and show encouraging outcomes in clinical trials, the need to scale up production to fulfill commercialization requirements is growing. The market's exponential expansion calls for the infrastructure and methods for biomanufacturing to be developed in a way that is economical, scalable, and efficient. To meet the rising demand for cell and gene therapy products, biomanufacturing businesses are investing in cutting-edge technology like automation, single-use systems, and closed-system bioreactors. In order to fulfill the demands of the quickly changing cell and gene therapy environment, the market's expansion is also encouraging partnerships, collaborations, and investments in biomanufacturing capacity. This is propelling the growth of the cell and gene therapy biomanufacturing market.
Insights on Market Segments The market segmentation for cell and gene therapy biomanufacturing comprises software solutions, equipment, and consumables depending on product type.
Commercial stage manufacturing and research stage manufacturing are included in the usage-based market segmentation.
Upstream, downstream, and harvesting processing are included in the market segmentation based on application.
Life Science Companies, Contract Research Organizations, Contract Manufacturing Organizations, and Cell Banks are included in the market segmentation of cell and gene therapy biomanufacturing based on End User.
Regional Perspectives The report offers market information for North America, Europe, Asia-Pacific, and the rest of the world, broken down by region. For a number of reasons, North America leads the world in cell and gene therapy biomanufacturing market share. First off, there is a thriving biotechnology and pharmaceutical industry in the area that is actively involved in cell and gene therapy research and development. Second, the production of cell and gene therapies is supported by well-established regulatory frameworks and regulations in North America, which promotes market expansion.
Because of its highly skilled workforce, the Europe cell and gene therapy biomanufacturing industry holds the second-largest market share. Due to a number of variables, Europe now holds the second-largest market share in the cell and gene therapy biomanufacturing industry. The area benefits from a highly skilled labor force, cutting-edge infrastructure, and a firmly established biopharmaceutical industry.
From 2024 to 2032, the Asia-Pacific Cell and Gene Therapy Biomanufacturing Market is anticipated to expand at the quickest Cap Rate. For a number of reasons, the cell and gene therapy biomanufacturing market is expanding at the fastest rate in the Asia Pacific area. First off, rising R&D expenditures, especially in cell and gene therapy, are the driving force behind the region's quickly growing biopharmaceutical sector.
Principal Players Thermo Fisher Scientific Inc., WuXi AppTec, Catalent, Inc., Samsung Biologics, FUJIFILM Diosynth Biotechnologies, Charles River Laboratories, Cytiva, Novasep, and Others are some of the leading companies in the cell and gene therapy biomanufacturing sector.